Fig. 5.

Combined AZD2014/dasatinib treatment elicits target inhibition in NF2-null lines. (A) Indicated cell lines were treated 24 h with DMSO, AZD2014, dasatinib, or AZD2014/dasatinib (Combination) followed by MIB/MS. LFQ intensities were log2 transformed and quantile normalized, and hierarchical clustering was performed. Values were mean-centered, and row z-score color key is shown. Strongly responsive “Dasatinib-Combination” cluster is shown. Cell lines and treatments are identified by color key. (B) Principal components analysis of LFQ intensities as in (A). Cell line is indicated by shape and treatment by color. (C–E) Volcano plots show log2 fold-change for each treatment (color-coded) versus DMSO plotted against the −10g10 Padj value. Dotted lines P = 0.05. (F) Immunoblotting shows induction of pAkt(T308) in NF2-null ACs after 24 h AZD2014 treatment.